New: Clinical trial search, funded by the National Cancer InstituteNew: NCI-funded clinical trial search

How has the GALAD score affected your practice for HCC screening?

Ask a clinical question

Answers grounded in the literature and physician expertise.

Related Questions

What clinical features would raise your suspicion for IgG-4 related disease?

How do you adjust transplant-benefit–based decision-making for HCC patients with prior immune checkpoint inhibitor exposure, given the potential for increased peri-transplant rejection or graft loss?

How do you incorporate tumor biology signals (e.g., AFP trajectory, radiographic growth kinetics, response durability) into a transplant-benefit framework, and when would adverse biology override a high modeled benefit for transplantation?

About Mednet

A community where doctors find answers to medicine's toughest questions.

Verified, credentialed physicians
45,000+ members across 23 specialties
Free CME and MOC credit

Evidence Meets Expertise

Community

Browse Specialties
Code of Conduct
AI Community Guidelines

Tools

Mednet AI
TrialMatch
Mobile App

Company

About
Careers
Events
Our Work
Blog

Support

FAQs
Contact Us
Programs

Legal

Privacy Policy
Terms of Service

© 2026 Mednet Inc. All rights reserved.